Related Experiment Video
Updated: Aug 5, 2026

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
Systematic gravity-induced posterior tumour drift in free-breathing lung stereotactic ablative radiotherapy
Lars Merring-Mikkelsen1, Hella M B Sand1,2, Mads H Brincker1
1Department of Medical Physics, Oncology, Aalborg University Hospital, Aalborg, Denmark.
Background And Purpose:
Intra-fractional respiratory tumour motion is a known challenge in lung stereotactic ablative radiotherapy (SABR), as it can compromise target dose coverage. Gravity-induced tumour baseline drift during free-breathing carries the same risk but remains uncharacterised. This study aimed to quantify posterior tumour drift in peripheral lung SABR, investigate predictive factors, and evaluate tumour dose coverage.
Materials And Methods:
In total, 97 patients (102 tumours) treated with 67.5 Gy in 3 fractions were analysed. Pre- and post-treatment cone beam computed tomography (CBCT) imaging quantified intra-fractional shifts at the first and second fraction. Temporal linear regression determined patient-specific drift rates. Correlations between drift rates and patient and tumour parameters were assessed. Plans were recalculated for worst-case drifts exceeding the 4 mm posterior planning target volume (PTV) margin.
Results:
Systematic posterior drift was observed, with mean vertical shifts of -1.45 mm at the first fraction and - 1.24 mm at the second fraction (both p < 0.001). Mean lateral and longitudinal shifts were negligible. No correlations with patient or tumour characteristics were identified. Based on drift rates, 15.7% of patients would exceed the 4 mm posterior margin within a 20-min treatment. Recalculated plans revealed severe gross tumour volume (GTV) underdosage: mean D90% coverage decreased from 99.9% to 74.2% (p < 0.001) under worst-case scenarios.
Conclusions:
Gravity-induced posterior drift represents a systematic, clinically significant phenomenon in free-breathing lung SABR. In 15.7% of patients, drifts exceeded planning margins, with potentially severe target underdosage. Routine post-treatment CBCT verification is recommended to identify at-risk patients, enabling intervention at subsequent fractions to ensure treatment accuracy.

